{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:32:14Z","timestamp":1791297134499,"version":"4.1.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.vaccine.2014.01.040","type":"journal-article","created":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T01:30:17Z","timestamp":1391131817000},"page":"1326-1337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":162,"title":["A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available"],"prefix":"10.1016","volume":"32","author":[{"given":"Tomohiro","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.01.040_bib0005","series-title":"Fields virology","first-page":"712","article-title":"Flaviviridae","author":"Lindenbach","year":"2013"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/rmv.712","article-title":"Neuroinvasive flavivirus infections","volume":"22","author":"Sips","year":"2012","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0015","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1749-6632.2001.tb02702.x","article-title":"Current status of flavivirus vaccines","volume":"951","author":"Barrett","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0020","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.vaccine.2008.12.063","article-title":"Immunoprophylaxis against important virus disease of horses, farm animals and birds","volume":"27","author":"Patel","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0025","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1473-3099(11)70147-5","article-title":"The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever","volume":"11","author":"Jentes","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/rmv.1752","article-title":"Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever","volume":"23","author":"Quaresma","year":"2013","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0035","unstructured":"World Health Organization. WHO Division of Epidemiological Surveillance and Health Situation Trend Assessment Global Health Situation and Projections\u2014Estimates. Geneva, Switzerland; 1992."},{"key":"10.1016\/j.vaccine.2014.01.040_bib0040","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/jama.300.8.960","article-title":"Yellow fever: 100 years of discovery","volume":"300","author":"Staples","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0045","first-page":"77","article-title":"The yellow fever vaccine: a history","volume":"83","author":"Frierson","year":"2010","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0050","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1084\/jem.65.6.787","article-title":"The use of yellow fever virus modified by in vitro cultivation for human immunization","volume":"65","author":"Theiler","year":"1937","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0055","unstructured":"World Health Organization. Yellow Fever Initiative, Providing an opportunity of a lifetime. YFIbrochure. Available at: http:\/\/www.who.int\/csr\/disease\/yellowfev\/YFIbrochure.pdf."},{"key":"10.1016\/j.vaccine.2014.01.040_bib0060","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1590\/S0034-89102004000500009","article-title":"Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial","volume":"38","author":"Camacho","year":"2004","journal-title":"Rev Saude Publica"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0065","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4269\/ajtmh.1999.60.1045","article-title":"Comparison of the immunogenicity and safety of two 17D yellow fever vaccines","volume":"60","author":"Lang","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0070","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AEM.25.4.539-544.1973","article-title":"Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0075","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0080","first-page":"895","article-title":"Persistence of neutralizing antibody 30\u201335 years after immunization with 17D yellow fever vaccine","volume":"59","author":"Poland","year":"1981","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0085","first-page":"178","article-title":"Yellow fever in Africa: public health impact and prospects for control in the 21st century","volume":"22","author":"Tomori","year":"2002","journal-title":"Biomedica"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0090","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0095","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","article-title":"Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases","volume":"358","author":"Vasconcelos","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","article-title":"Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases","volume":"358","author":"Martin","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(01)05341-7","article-title":"Hepatitis and death following vaccination with 17D-204 yellow fever vaccine","volume":"358","author":"Chan","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0110","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1016\/j.vaccine.2011.04.055","article-title":"Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review","volume":"29","author":"Thomas","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0115","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0120","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.vaccine.2013.01.054","article-title":"Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010","volume":"31","author":"Breugelmans","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0125","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0130","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4269\/ajtmh.1959.8.698","article-title":"Ecologic studies of Japanese encephalitis virus in Japan. VI. Swine infection","volume":"8","author":"Scherer","year":"1959","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.ento.54.110807.090510","article-title":"Ecology and geographical expansion of Japanese encephalitis virus","volume":"54","author":"van den Hurk","year":"2009","journal-title":"Annu Rev Entomol"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid1501.080311","article-title":"Past, present, and future of Japanese encephalitis","volume":"15","author":"Erlanger","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0145","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2217\/fvl.10.55","article-title":"Combating Japanese encephalitis: Vero-cell derived inactivated vaccines and the situation in Japan","volume":"5","author":"Ishikawa","year":"2010","journal-title":"Future Virol"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0150","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0155","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0160","first-page":"55","article-title":"A controlled field trial for an evaluation of effectiveness of mouse-brain Japanese encephalitis vaccine","volume":"70","author":"Hsu","year":"1971","journal-title":"Taiwan Yi Xue Hui Za Zhi"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0165","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1056\/NEJM198809083191004","article-title":"Protection against Japanese encephalitis by inactivated vaccines","volume":"319","author":"Hoke","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0170","first-page":"658","article-title":"Japanese encephalitis surveillance and immunization \u2013 Asia and the Western pacific, 2012","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0175","doi-asserted-by":"crossref","first-page":"333","DOI":"10.7883\/yoken.JJID.2008.333","article-title":"Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004","volume":"61","author":"Arai","year":"2008","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0180","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1748-5967.2007.00124.x","article-title":"Historical review and surveillance of Japanese encephalitis, Republic of Korea, 2002\u20132004","volume":"37","author":"Kim","year":"2007","journal-title":"Entomol Res"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0185","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4269\/ajtmh.1999.61.78","article-title":"The epidemiology of Japanese encephalitis on Taiwan during 1966\u20131997","volume":"61","author":"Wu","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0190","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0195","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1016\/j.vaccine.2008.05.081","article-title":"Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study","volume":"26","author":"Schuller","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0200","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.vaccine.2008.12.062","article-title":"Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study","volume":"27","author":"Schuller","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0205","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1016\/j.vaccine.2011.08.117","article-title":"Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO((R))","volume":"29","author":"Schuller","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0210","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.vaccine.2009.10.024","article-title":"Immunogenicity and safety of IXIARO((R)) (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age","volume":"28","author":"Kaltenbock","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0215","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.vaccine.2012.01.054","article-title":"Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated)","volume":"30","author":"Kikukawa","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0220","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1016\/j.vaccine.2012.07.034","article-title":"Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (Inactivated) (JEBIK((R))V) in children","volume":"30","author":"Okada","year":"2012","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2014.01.040_bib0225","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1016\/S0264-410X(03)00506-1","article-title":"Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine","volume":"21","author":"Kuzuhara","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0230","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/14712598.8.1.95","article-title":"Current use and development of vaccines for Japanese encephalitis","volume":"8","author":"Beasley","year":"2008","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2014.01.040_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0264-410X(00)00037-2","article-title":"New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO\/CVI meeting, Bangkok, Thailand, 13\u201315 October 1998","volume":"18","author":"Tsai","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0240","series-title":"The 63rd WHO Expert Committee on Biological Standardization. Recommendations to assure the quality, safety and efficacy of Japanese encephalitis vaccine (live, attenuated) for human use","year":"2012"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0245","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue. West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0250","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/INF.0b013e3181f68e9c","article-title":"Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial","volume":"29","author":"Chokephaibulkit","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0255","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1016\/j.vaccine.2010.09.035","article-title":"Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials","volume":"28","author":"Torresi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0260","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4161\/hv.20071","article-title":"Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12\u201318 months: randomized, controlled phase 3 immunogenicity and safety trial","volume":"8","author":"Feroldi","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0265","doi-asserted-by":"crossref","first-page":"9847","DOI":"10.1128\/JVI.00825-11","article-title":"Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia","volume":"85","author":"Pan","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0270","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/cid\/cis883","article-title":"Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes","volume":"56","author":"Erra","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0275","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.4161\/hv.23802","article-title":"Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines","volume":"9","author":"Amicizia","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0280","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1099\/vir.0.011437-0","article-title":"Tick-borne encephalitis virus \u2013 a review of an emerging zoonosis","volume":"90","author":"Mansfield","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0285","first-page":"241","article-title":"Vaccines against tick-borne encephalitis: WHO position paper","volume":"86","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0290","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.vaccine.2010.12.048","article-title":"Tick-borne encephalitis: the impact of epidemiology, changing lifestyle, and environmental factors. Conference report of the 12th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE)","volume":"29","author":"Kunze","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0295","doi-asserted-by":"crossref","DOI":"10.2807\/ese.16.39.19976-en","article-title":"Tick-borne encephalitis in Europe, 2007 to 2009","volume":"16","author":"Donoso Mantke","year":"2011","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0300","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0264-410X(01)00329-2","article-title":"Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination","volume":"20","author":"Marth","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0305","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000977.pub2","article-title":"Vaccines for preventing tick-borne encephalitis","volume":"21","author":"Demicheli","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0310","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1016\/j.vaccine.2011.07.089","article-title":"Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme","volume":"29","author":"Loew-Baselli","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0315","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1016\/S0264-410X(03)00421-3","article-title":"Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer","volume":"21","author":"Zent","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0320","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0264-410X(02)00592-3","article-title":"Clinical evaluation of a polygeline-free tick-borne encephalitis vaccine for adolescents and adults","volume":"21","author":"Zent","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0325","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.vaccine.2008.11.082","article-title":"Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults","volume":"27","author":"Plentz","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0330","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.vaccine.2008.12.057","article-title":"Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur Children","volume":"27","author":"Wittermann","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0335","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.vaccine.2009.02.069","article-title":"Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human","volume":"27","author":"Leonova","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0340","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3201\/eid1901.120458","article-title":"Vaccination and tick-borne encephalitis, central Europe","volume":"19","author":"Heinz","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0345","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.vaccine.2011.12.013","article-title":"Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes","volume":"30","author":"Fritz","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0350","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/infdis\/jir122","article-title":"A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans","volume":"203","author":"Orlinger","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0355","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(07)61687-0","article-title":"Dengue","volume":"370","author":"Halstead","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0360","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nrmicro2595","article-title":"Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health","volume":"9","author":"Vasilakis","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0365","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1128\/CMR.11.3.480","article-title":"Dengue and dengue hemorrhagic fever","volume":"11","author":"Gubler","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0370","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0375","first-page":"83","article-title":"Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis","volume":"338","author":"Rothman","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0380","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/315215","article-title":"Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity","volume":"181","author":"Vaughn","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0385","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"Neutralization and antibody-dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0390","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","article-title":"Research on dengue during World War II","volume":"1","author":"Sabin","year":"1952","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0395","first-page":"301","article-title":"Immune enhancement of viral infection","volume":"31","author":"Halstead","year":"1982","journal-title":"Prog Allergy"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0400","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2007.02.079","article-title":"Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17\u201318 November 2005","volume":"25","author":"Hombach","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0405","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4269\/ajtmh.2002.66.264","article-title":"Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses","volume":"66","author":"Sabchareon","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0410","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690024","article-title":"Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates","volume":"69","author":"Sun","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0415","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4161\/hv.5.1.6348","article-title":"Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults","volume":"5","author":"Sun","year":"2009","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0420","first-page":"308","article-title":"Understanding dengue pathogenesis: implications for vaccine design","volume":"83","author":"Stephenson","year":"2005","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0425","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.vaccine.2005.09.029","article-title":"Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults","volume":"24","author":"Kitchener","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0430","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4269\/ajtmh.2012.12-0361","article-title":"A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults","volume":"88","author":"Thomas","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0435","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0440","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0445","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0450","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","article-title":"Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine","volume":"29","author":"Durbin","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0455","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1016\/j.vaccine.2013.05.075","article-title":"Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles","volume":"31","author":"Lindow","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0460","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0465","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1016\/j.vaccine.2011.07.021","article-title":"The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease","volume":"29","author":"Coller","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0470","unstructured":"World Health Organization. Dengue Vaccine Initiative, Subunit, Inactivated Vaccines & DNA Vaccines. Available at: http:\/\/www.denguevaccines.org\/subunit-and-inactivated-vaccines."},{"key":"10.1016\/j.vaccine.2014.01.040_bib0475","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.vaccine.2010.11.050","article-title":"Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial","volume":"29","author":"Beckett","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0480","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.vaccine.2011.10.085","article-title":"Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine","volume":"30","author":"Porter","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0485","first-page":"38","article-title":"An effective dengue vaccine: a glass half full or half empty","volume":"26","author":"Arya","year":"2013","journal-title":"Natl Med J India"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0490","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(12)61510-4","article-title":"Dengue vaccine development: a 75% solution","volume":"380","author":"Halstead","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0495","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1473-3099(13)70028-8","article-title":"Dengue vaccine efficacy trial: does interference cause failure","volume":"13","author":"Swaminathan","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0500","doi-asserted-by":"crossref","first-page":"e2126","DOI":"10.1371\/journal.pntd.0002126","article-title":"Challenges in the interpretation of dengue vaccine trial results","volume":"7","author":"Rodriguez-Barraquer","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0505","unstructured":"Questions and Answers on Dengue Vaccines: Phase IIb study of CYD-TDV. Available at: http:\/\/www.who.int\/immunization\/research\/committees\/WHO_dengue_vaccine_QA_september2012.pdf."},{"key":"10.1016\/j.vaccine.2014.01.040_bib0510","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1016\/j.vaccine.2013.10.013","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2\u201311 years in Malaysia: a randomized, placebo-controlled, Phase III study","volume":"31","author":"Hss","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0515","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4269\/ajtmh.2009.80.61","article-title":"An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells","volume":"80","author":"Rodrigo","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0520","doi-asserted-by":"crossref","first-page":"e1536","DOI":"10.1371\/journal.pntd.0001536","article-title":"Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcgammaR-expressing cells","volume":"6","author":"Moi","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0525","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1743-422X-9-115","article-title":"Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement","volume":"9","author":"Hughes","year":"2012","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0530","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3389\/fimmu.2012.00334","article-title":"Sculpting humoral immunity through dengue vaccination to enhance protective immunity","volume":"3","author":"Crill","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0535","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.antiviral.2008.06.010","article-title":"Mouse models of dengue virus infection and disease","volume":"80","author":"Yauch","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0540","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1099\/vir.0.031229-0","article-title":"Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity","volume":"92","author":"Omatsu","year":"2011","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0545","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/infdis\/jis744","article-title":"Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines","volume":"207","author":"Sun","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0550","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/infdis\/jis749","article-title":"The dengue human challenge model: has the time come to accept this challenge","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0555","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cll.2009.10.006","article-title":"West Nile virus","volume":"30","author":"Rossi","year":"2010","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0560","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S1466252307001430","article-title":"Transmission dynamics and changing epidemiology of West Nile virus","volume":"9","author":"Blitvich","year":"2008","journal-title":"Anim Health Res Rev"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0565","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1863-2378.2008.01208.x","article-title":"The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and Australasia: the potential for emergent viruses","volume":"56","author":"Mackenzie","year":"2009","journal-title":"Zoonoses Public Health"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0570","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1017\/S0950268811000185","article-title":"The virology, epidemiology, and clinical impact of West Nile virus: a decade of advancements in research since its introduction into the Western Hemisphere","volume":"139","author":"Murray","year":"2011","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0575","first-page":"1","article-title":"Surveillance for human West Nile virus disease \u2013 United States, 1999\u20132008","volume":"59","author":"Lindsey","year":"2010","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0580","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1016\/j.vaccine.2006.12.005","article-title":"West Nile virus: recent trends in diagnosis and vaccine development","volume":"25","author":"Dauphin","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0585","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1297-9716-43-16","article-title":"Recent progress in West Nile virus diagnosis and vaccination","volume":"43","author":"De Filette","year":"2012","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0590","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jiq003","article-title":"Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults","volume":"203","author":"Biedenbender","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0595","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1016\/j.vaccine.2012.08.063","article-title":"Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults \u2265 50 years of age","volume":"30","author":"Dayan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0600","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1016\/j.vaccine.2013.07.064","article-title":"The live attenuated chimeric vaccine rWN\/DEN4Delta30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers","volume":"31","author":"Durbin","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0605","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial","volume":"203","author":"Ledgerwood","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0610","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1128\/CVI.00119-09","article-title":"Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys","volume":"16","author":"Lieberman","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.01.040_bib0615","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3201\/eid1203.050782","article-title":"Cost-effectiveness of West Nile virus vaccination","volume":"12","author":"Zohrabian","year":"2006","journal-title":"Emerg Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14000747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14000747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T04:35:01Z","timestamp":1688963701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14000747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":123,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0264410X14000747"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.01.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.01.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}